BridgeBio Pharma, Inc.

As of June 30, 2026, BridgeBio Pharma, Inc. carries a market capitalization of 12.44B, placing it among publicly traded companies globally. Its enterprise value stands at 14.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BridgeBio Pharma, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, BridgeBio Pharma, Inc. has 195.28M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 19.80, and the price-to-book ratio stands at -5.65.

These figures are as of June 30, 2026. The EV/Sales ratio of 22.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 14.00B versus a market cap of 12.44B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BridgeBio Pharma, Inc. maintains a current ratio of 1.23, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -99.52, indicating conservative leverage, while an interest coverage ratio of -2.39 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -60.23, reflecting losses generated across the asset base. The company generates approximately 768,893.50 in revenue per employee across its workforce of 811.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.12 indicates how many times BridgeBio Pharma, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BridgeBio Pharma, Inc. recorded an income tax benefit of -1.46M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -615.93M and -605.59M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 62.06, while the 200-day moving average is 62.74.

Over the twelve months ended June 30, 2026, BridgeBio Pharma, Inc. generated 624.15M in revenue and converted that into -605.59M in net income, yielding earnings per share of -3.17. EBITDA reached -431.28M, while operating income came in at -418.24M.

As of June 30, 2026, BridgeBio Pharma, Inc. holds 630.36M in cash and equivalents against 2.18B in total debt, resulting in a net debt position of 1.57B. Total book value stands at -2.20B, with working capital of 177.24M providing operational flexibility.

BridgeBio Pharma, Inc. produced -380.21M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.99M in capital expenditures, free cash flow totaled -383.20M - equivalent to -1.98 per share.

Over the twelve months ended June 30, 2026, BridgeBio Pharma, Inc. posted a gross margin of 94.44, reflecting its pricing power and cost economics. The operating margin of -67.01 and net profit margin of -97.03 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.10: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.80, meaning BridgeBio Pharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, BridgeBio Pharma, Inc. has an Altman Z-Score of -3.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.